Retrophin Inc. (RTRX) PT Raised to $46.00
Retrophin Inc. (NASDAQ:RTRX) had its target price boosted by equities researchers at BMO Capital Markets to $46.00 in a report issued on Monday. BMO Capital Markets’ price objective would indicate a potential upside of 129.08% from the company’s previous close.
RTRX has been the subject of a number of other reports. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Wednesday, October 12th. JMP Securities restated a “buy” rating on shares of Retrophin in a research note on Friday, November 11th. TheStreet downgraded Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, November 4th. Finally, Leerink Swann lifted their target price on Retrophin from $27.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $29.60.
Retrophin (NASDAQ:RTRX) traded up 5.63% on Monday, reaching $21.21. The company’s stock had a trading volume of 564,101 shares. The company’s market cap is $800.30 million. Retrophin has a 12 month low of $11.60 and a 12 month high of $24.57. The company has a 50-day moving average price of $20.71 and a 200 day moving average price of $18.80.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.38 by $0.47. The company earned $33.95 million during the quarter, compared to the consensus estimate of $34.84 million. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) earnings per share. On average, equities research analysts anticipate that Retrophin will post ($1.32) EPS for the current fiscal year.
In related news, EVP Alvin Shih sold 8,750 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $16.24, for a total value of $142,100.00. Following the completion of the sale, the executive vice president now directly owns 158,334 shares in the company, valued at approximately $2,571,344.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.41% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Scopia Capital Management LP increased its stake in Retrophin by 874.8% in the first quarter. Scopia Capital Management LP now owns 3,598,222 shares of the biopharmaceutical company’s stock valued at $49,152,000 after buying an additional 3,229,087 shares during the period. BlackRock Fund Advisors increased its stake in Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock valued at $17,799,000 after buying an additional 22,903 shares during the period. GSA Capital Partners LLP increased its stake in Retrophin by 68.6% in the second quarter. GSA Capital Partners LLP now owns 46,509 shares of the biopharmaceutical company’s stock valued at $828,000 after buying an additional 18,920 shares during the period. Boston Advisors LLC increased its stake in Retrophin by 23.8% in the second quarter. Boston Advisors LLC now owns 26,945 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 5,185 shares during the period. Finally, First Mercantile Trust Co. increased its stake in Retrophin by 35.4% in the second quarter. First Mercantile Trust Co. now owns 5,930 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,550 shares during the period.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.